SS Innovations Reports 39.4% Revenue Growth to $13.9M Despite Increased Net Loss

SS Innovations International, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company achieved total revenues of $13.9 million for the three months ended June 30, 2026, marking a 39.4% increase from $10 million in the same period last year. This growth was primarily driven by a rise in system sales, which reached $12.4 million, up from $8.8 million in the prior year. However, the company also reported a net loss of $2.7 million for the quarter, compared to a loss of $256,691 in the previous year, reflecting increased operational costs, particularly in research and development.

For the six months ending June 30, 2026, SS Innovations reported total revenues of $25 million, a substantial increase from $15.1 million in the same period of 2025. The gross profit for the first half of 2026 was $12.4 million, compared to $7 million in the prior year. Despite this revenue growth, the company incurred a net loss of $6.2 million for the six months, slightly higher than the $5.9 million loss reported in the same period last year. The increase in losses was attributed to higher research and development expenses, which rose to $3.4 million from $1.5 million, as well as increased selling, general, and administrative expenses.

In terms of operational metrics, SS Innovations sold 46 SSi Mantra surgical robotic systems during the first half of 2026, with 26 systems sold in the second quarter alone. The company has also expanded its geographic footprint, with 93% of its revenue coming from India, up from 77% in the previous year. The company’s cash and cash equivalents increased significantly to $13.6 million as of June 30, 2026, compared to $3.2 million at the end of 2025, bolstered by a private placement that raised $18.4 million in March 2026.

Strategically, SS Innovations has focused on enhancing its product offerings and expanding its market presence. The company is actively pursuing regulatory approvals for its products in the U.S. and European markets, which are critical for its growth strategy. The filing also noted that the company is investing in research and development to improve its surgical robotic systems and related technologies, aiming to make robotic surgery more accessible and affordable.

Looking ahead, SS Innovations anticipates that its ongoing efforts in product development and market expansion will drive future revenue growth. However, the company acknowledged that it may continue to incur losses as it scales its operations and invests in regulatory compliance. Management is actively seeking additional funding to support its growth initiatives and ensure operational sustainability in the coming months.